AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

- 1-22. (Cancelled)
- 23. (Currently Amended) A method of improving acceptance and osseous integration of a bone implants implant in a subject, which method comprises administering to a the subject in need of such improvement a therapeutically effective amount of an agent comprising creatine pyruvate or an analogue thereof, to improve acceptance and osseous integration of a bone implant, wherein the agent is administered in an amount of 1.4 to 285 mg per day.
- 24. (Currently Amended) A method for accelerating healing in a subject having a defect in bone or cartilage tissue caused by trauma or surgery, which method comprises administering to the subject in need thereof a therapeutically effective amount of an agent comprising creatine pyruvate or an analogue thereof, wherein the agent is administered in an amount of 1.4 to 285 mg per day.
- 25-30. (Cancelled)
- 31. (New) The method of claim 23, wherein the subject is an animal.
- 32. (New) The method of claim 23, wherein the subject is a human.
- 33. (New) The method of claim 32, wherein the agent is administered in an amount of 1.4 to 285 mg per day.
- 34. (New) The method of claim 24, wherein the subject is an animal.
- 35. (New) The method of claim 24, wherein the subject is a human.
- 36. (New) The method of claim 35, wherein the agent is administered in an amount of 1.4 to 285 mg per day.
- 37. (New) A method for accelerating healing in a subject having a defect in bone or cartilage tissue caused by trauma or surgery, which method comprises administering to the

Appl. No. 09/769,404 Amdt. dated April 17, 2007 Reply to final Office Action mailed Jan. 17, 2007

subject in need thereof a therapeutically effective amount of a composition comprising (1) an agent comprising creatine pyruvate or an analogue thereof, and (2) a pharmaceutically acceptable carrier.

- 38. (New) The method of claim 37, wherein the composition is in a sustained release formulation.
- 39. (New) The method of claim 37, wherein the subject is an animal.
- 40. (New) The method of claim 37, wherein the subject is a human.
- 41. (New) The method of claim 40, wherein the agent is administered in an amount of 1.4 to 285 mg per day.